"Tosyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Toluenesulfonyl compounds with general formula CH3C6H4S(O2)R” widely used to block amino groups in the course of syntheses of drugs and other biologically active compounds.
| Descriptor ID |
D014105
|
| MeSH Number(s) |
D02.455.426.559.389.832.661 D02.886.590.887
|
| Concept/Terms |
Tosyl Compounds- Tosyl Compounds
- Compounds, Tosyl
- Toluenesulfonyl Compounds
- Compounds, Toluenesulfonyl
|
Below are MeSH descriptors whose meaning is more general than "Tosyl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Tosyl Compounds".
This graph shows the total number of publications written about "Tosyl Compounds" by people in this website by year, and whether "Tosyl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tosyl Compounds" by people in Profiles.
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024 Dec; 13(24):e70226.
-
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. Eur Urol Oncol. 2025 Jun; 8(3):612-615.
-
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 07 01; 7(7):e2419966.
-
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
-
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
-
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
-
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 Aug; 41(2):425-32.
-
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010 Apr; 151(4):1409-17.
-
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One. 2008; 3(11):e3605.
-
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 2007 Sep 01; 67(17):8388-95.